Should You Buy Pacira Pharmaceuticals Inc (PCRX)?

Consequently, key money managers were breaking ground themselves. Armistice Capital, led by Steven Boyd, initiated the most valuable position in Pacira Pharmaceuticals Inc (NASDAQ:PCRX). Armistice Capital had $9.2 million invested in the company at the end of the quarter. Solomon Kumin’s Folger Hill Asset Management also made a $8.6 million investment in the stock during the quarter. The other funds with brand new PCRX positions are Kevin Kotler’s Broadfin Capital, Stuart Weisbrod’s Iguana Healthcare Management, and Glenn Russell Dubin’s Highbridge Capital Management.

Let’s now review hedge fund activity in other stocks similar to Pacira Pharmaceuticals Inc (NASDAQ:PCRX). These stocks are Third Point Reinsurance Ltd (NYSE:TPRE), SunPower Corporation (NASDAQ:SPWR), Terreno Realty Corporation (NYSE:TRNO), and AVG Technologies NV (NYSE:AVG). This group of stocks’ market caps resemble PCRX’s market cap.

As you can see these stocks had an average of 13 hedge funds with bullish positions and the average amount invested in these stocks was $41 million. That figure was $266 million in PCRX’s case. SunPower Corporation (NASDAQ:SPWR) is the most popular stock in this table. On the other hand Terreno Realty Corporation (NYSE:TRNO) is the least popular one with only 9 bullish hedge fund positions. Compared to these stocks Pacira Pharmaceuticals Inc (NASDAQ:PCRX) is more popular among hedge funds. Considering that hedge funds are fond of this stock in relation to its market cap peers, it may be a good idea to analyze it in detail and potentially include it in your portfolio.

Disclosure: None